News
Catalent and S.Biomedics join forces to advance groundbreaking Parkinson’s therapy
TED?A9 is part of S.Biomedics’ expanding pipeline of stem-cell-based therapies, developed using the company’s proprietary targeted embryonic stem cell differentiation platform
- By IPP Bureau
| February 19, 2026
Catalent and S.Biomedics have announced a strategic partnership to develop and manufacture TED‑A9, an allogeneic pluripotent stem-cell-derived therapy targeting Parkinson’s disease. The collaboration aims to accelerate the therapy from pivotal studies toward potential commercialization.
“Catalent’s advanced cell therapy development and manufacturing capabilities are designed to help innovators like S.Biomedics move confidently through pivotal studies toward commercial readiness,” said David McErlane, Group President, Biologics at Catalent.
“We are proud to work together to build a robust, scalable foundation that can accelerate access to this promising therapy for patients and families worldwide.”
TED‑A9 is part of S.Biomedics’ expanding pipeline of stem-cell-based therapies, developed using the company’s proprietary targeted embryonic stem cell differentiation (TED) platform. The therapy is designed as a ventral midbrain–specific dopaminergic precursor cell treatment for patients with Parkinson’s disease.
“Initiating our first U.S. clinical study, which is designed as a pivotal trial, represents a critical step toward delivering new treatment options to patients,” said Tony Kang, CEO of S.Biomedics.
“We are pleased to partner with Catalent, a global leader in cell therapy CDMO services, as we establish a scalable, GMP‑ready manufacturing foundation to support pivotal development and enable a potential path toward future commercialization, with the ultimate goal of bringing hope to patients and families affected by Parkinson’s disease worldwide.”
Catalent will leverage its global network and expertise in cell therapy development, analytical services, and GMP manufacturing to support TED‑A9, spanning early development through clinical and commercial launch.
